Skip to main content
AML drug gains orphan status
10/10/2017

Trovagene's drug candidate PCM-075 received FDA orphan status as a treatment for acute myeloid leukemia. The oral drug inhibits the serine/threonine Polo-like Kinase 1 enzyme, which is over-expressed in a number of blood and other cancers.

Full Story: